IRF1 and neoplasm: Recent research has delineated two predominant subpopulations of chemotherapy-resistant senescent tumor cells: one subset enhances PD-L1 expression through an IFNγ/IRF1-mediated pathway, while another subset elevates CD80 expression via a p53-dependent mechanism [126].